Home
Portfolio
Probably Genetic
exit

Probably Genetic’s builds highly specific and efficient patient recruiting pipelines for biotech companies by identifying patients with super-rare diseases.

D2C DNA test to help identify super-rare disease patients

PROBLEM

400+ million people worldwide are suffering from rare genetic conditions but only 5% of known rare diseases have FDA approved medication available. Biotech companies are struggling to find treatments because of the complexities related to identifying patients for their clinical studies. The rarer a disease, the harder it is to do research on it and find a cure.

SOLUTION

Probably Genetic combines genetic science and a sophisticated toolkit of NLP-assisted online marketing methods to find and assess potential rare disease patients. Clinical-grade, fast and affordable DNA tests help identify the right patients, who can then be referred to clinical studies. This benefits individuals as well the biotech companies conducting research.





Team members

Lukas Lange
Harley Katz

Stage
Seed
Sector
Digital Health
Year invested
2020

Related Article

Lukas Lange is an expert in genomics and the CEO of Probably Genetic, which he founded together with CTO Harley Katz in 2019.

Lukas Lange
Co-Founder & CEO Probably Genetic

More Use Cases

We are a fund built
by founders for founders

Successful founders supporting new founders in a way not yet seen in European venture capital. Let us be part of your journey!

Submit your pitch